Massoud Saberinia, MD
Endocrinology, Diabetes & Metabolism · Arlington, VANPI 1962437079
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 445 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by Lilly USA, LLC at 28.9% of the total.
Across 445 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Boehringer Ingelheim$1K
- Novo Nordisk$839
- Sanofi-aventis U.S. LLC$479
- Amgen$346
- Amneal Pharmaceuticals LLC$332
- plus $2K from 30 others
What the payments were for
- Food & beverage$7,40198%
- Education$1282%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 114 | $2,175 |
| Boehringer Ingelheim | 118 | $1,243 |
| Novo Nordisk | 47 | $839 |
| Sanofi-aventis U.S. LLC | 24 | $479 |
| Amgen(2 entities) | 18 | $346 |
| Amneal Pharmaceuticals LLC | 27 | $332 |
| AbbVie(2 entities) | 15 | $238 |
| Medtronic(2 entities) | 7 | $230 |
| Insulet Corporation | 8 | $207 |
| BETA Bionics, Inc. | 8 | $165 |
| IBSA Pharma Inc. | 6 | $126 |
| Merck | 6 | $122 |
| Tandem Diabetes Care, Inc. | 6 | $111 |
| Xeris Pharmaceuticals, Inc. | 4 | $89 |
| Dexcom, Inc. | 3 | $87 |
| Bayer | 4 | $69 |
| Amarin Pharma, Inc. | 3 | $62 |
| Ascendis Pharma Endocrinology Inc | 2 | $59 |
| Amphastar Pharmaceuticals, Inc. | 3 | $54 |
| Embecta Corp. | 2 | $48 |
| Mannkind Corporation | 2 | $43 |
| Corcept Therapeutics | 1 | $40 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Abbott | 2 | $39 |
| Antares Pharma, Inc. | 2 | $37 |
| Lifescan, Inc. | 1 | $32 |
| Sequel Med Tech, LLC | 1 | $30 |
| Acella Pharmaceuticals, LLC | 1 | $24 |
| Companion Medical, Inc. | 1 | $24 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| Pfizer | 1 | $20 |
| AstraZeneca | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 630G$112
How this compares
$7,529 in reported general payments places this provider in the 80th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 107 | $243,670 |
| JardianceEmpagliflozin | 104 | $162,352 |
| MounjaroTirzepatide | 69 | $117,484 |
| OzempicSemaglutide | 60 | $109,082 |
| FarxigaDapagliflozin Propanediol | 73 | $107,783 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 53 | $79,665 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 47 | $58,558 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $34,812 |
| ProliaDenosumab | 18 | $31,472 |
| Humalog Kwikpen U-200Insulin Lispro | 21 | $29,376 |
| Jentadueto XrLinagliptin/Metformin Hcl | 24 | $21,857 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $20,236 |
| Novolog FlexpenInsulin Aspart | 38 | $15,305 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $15,115 |
| JanuviaSitagliptin Phosphate | 14 | $14,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $2,175 | $365,435188 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Jentadueto Xr | $1,243 | $242,767175 claims |
| Novo NordiskOzempic, Novolog | $839 | $114,16872 claims |
| AstraZenecaFarxiga | $17 | $107,78373 claims |
| MerckJanumet Xr, Januvia | $122 | $93,90867 claims |
| AmgenProlia | $346 | $31,47218 claims |
| AbbVieSynthroid | $238 | $11,218137 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $332 | $5,773544 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Arlington
- Domenica RubinoArlington$608K
- Caroline HuangArlington$30K
- Thien-Giang Bach-HuynhArlington$8K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.